FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2142629029> ?p ?o ?g. }

• W2142629029 endingPage "810" @default.
• W2142629029 startingPage "804" @default.
• W2142629029 abstract "Abstract Purpose: To determine the safety, dose-limiting toxicity, maximum tolerated dose, and pharmacokinetic and pharmacodynamic profiles of the novel hydroxamate histone deacetylase inhibitor belinostat (previously named PXD101) in patients with advanced refractory solid tumors. Experimental Design: Sequential dose-escalating cohorts of three to six patients received belinostat administered as a 30-min i.v. infusion on days 1 to 5 of a 21-day cycle. Pharmacokinetic variables were evaluated at all dose levels. Pharmacodynamic measurements included acetylation of histones extracted from peripheral blood mononuclear cells, caspase-dependent cleavage of cytokeratin-18, and interleukin-6 levels. Results: Forty-six patients received belinostat at one of six dose levels (150-1,200 mg/m2/d). Dose-limiting toxicities were grade 3 fatigue (one patient at 600 mg/m2; one patient at 1,200 mg/m2), grade 3 diarrhea combined with fatigue (one patient at 1,200 mg/m2), grade 3 atrial fibrillation (one patient at 1,200 mg/m2; one patient at 1,000 mg/m2), and grade 2 nausea/vomiting leading to inability to complete a full 5-day cycle (two patients at 1,000 mg/m2). The maximum tolerated dose was 1,000 mg/m2/d. I.v. belinostat displayed linear pharmacokinetics with respect to Cmax and AUC. The intermediate elimination half-life was 0.3 to 1.3 h and was independent of dose. Histone H4 hyperacetylation was observed after each infusion and was sustained for 4 to 24 h in a dose-dependent manner. Increases in interleukin-6 levels were detected following belinostat treatment. Stable disease was observed in a total of 18 (39%) patients, including 15 treated for ≥4 cycles, and this was associated with caspase-dependent cleavage of cytokeratin-18. Of the 24 patients treated at the maximum tolerated dose (1,000 mg/m2/d), 50% achieved stable disease. Conclusions: I.v. belinostat is well tolerated, exhibits dose-dependent pharmacodynamic effects, and has promising antitumor activity." @default.
• W2142629029 created "2016-06-24" @default.
• W2142629029 creator A5004328721 @default.
• W2142629029 creator A5014220064 @default.
• W2142629029 creator A5015881755 @default.
• W2142629029 creator A5017949156 @default.
• W2142629029 creator A5023421349 @default.
• W2142629029 creator A5033192979 @default.
• W2142629029 creator A5053758493 @default.
• W2142629029 creator A5062636082 @default.
• W2142629029 creator A5064336901 @default.
• W2142629029 creator A5072378199 @default.
• W2142629029 creator A5076521860 @default.
• W2142629029 date "2008-02-01" @default.
• W2142629029 modified "2023-10-17" @default.
• W2142629029 title "A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors" @default.
• W2142629029 cites W1563624749 @default.
• W2142629029 cites W1602446144 @default.
• W2142629029 cites W2023695795 @default.
• W2142629029 cites W2059798026 @default.
• W2142629029 cites W2092722802 @default.
• W2142629029 cites W2134933569 @default.
• W2142629029 cites W2135085078 @default.
• W2142629029 cites W2149386327 @default.
• W2142629029 cites W2157511493 @default.
• W2142629029 cites W2243735979 @default.
• W2142629029 cites W2535178493 @default.
• W2142629029 doi "https://doi.org/10.1158/1078-0432.ccr-07-1786" @default.
• W2142629029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18245542" @default.
• W2142629029 hasPublicationYear "2008" @default.
• W2142629029 type Work @default.
• W2142629029 sameAs 2142629029 @default.
• W2142629029 citedByCount "227" @default.
• W2142629029 countsByYear W21426290292012 @default.
• W2142629029 countsByYear W21426290292013 @default.
• W2142629029 countsByYear W21426290292014 @default.
• W2142629029 countsByYear W21426290292015 @default.
• W2142629029 countsByYear W21426290292016 @default.
• W2142629029 countsByYear W21426290292017 @default.
• W2142629029 countsByYear W21426290292018 @default.
• W2142629029 countsByYear W21426290292019 @default.
• W2142629029 countsByYear W21426290292020 @default.
• W2142629029 countsByYear W21426290292021 @default.
• W2142629029 countsByYear W21426290292022 @default.
• W2142629029 countsByYear W21426290292023 @default.
• W2142629029 crossrefType "journal-article" @default.
• W2142629029 hasAuthorship W2142629029A5004328721 @default.
• W2142629029 hasAuthorship W2142629029A5014220064 @default.
• W2142629029 hasAuthorship W2142629029A5015881755 @default.
• W2142629029 hasAuthorship W2142629029A5017949156 @default.
• W2142629029 hasAuthorship W2142629029A5023421349 @default.
• W2142629029 hasAuthorship W2142629029A5033192979 @default.
• W2142629029 hasAuthorship W2142629029A5053758493 @default.
• W2142629029 hasAuthorship W2142629029A5062636082 @default.
• W2142629029 hasAuthorship W2142629029A5064336901 @default.
• W2142629029 hasAuthorship W2142629029A5072378199 @default.
• W2142629029 hasAuthorship W2142629029A5076521860 @default.
• W2142629029 hasBestOaLocation W21426290291 @default.
• W2142629029 hasConcept C104317684 @default.
• W2142629029 hasConcept C111113717 @default.
• W2142629029 hasConcept C112705442 @default.
• W2142629029 hasConcept C126322002 @default.
• W2142629029 hasConcept C185592680 @default.
• W2142629029 hasConcept C197934379 @default.
• W2142629029 hasConcept C22979827 @default.
• W2142629029 hasConcept C2776202225 @default.
• W2142629029 hasConcept C2778305200 @default.
• W2142629029 hasConcept C2778375690 @default.
• W2142629029 hasConcept C2780580376 @default.
• W2142629029 hasConcept C2780852908 @default.
• W2142629029 hasConcept C29730261 @default.
• W2142629029 hasConcept C55493867 @default.
• W2142629029 hasConcept C64927066 @default.
• W2142629029 hasConcept C71924100 @default.
• W2142629029 hasConcept C90924648 @default.
• W2142629029 hasConcept C98274493 @default.
• W2142629029 hasConceptScore W2142629029C104317684 @default.
• W2142629029 hasConceptScore W2142629029C111113717 @default.
• W2142629029 hasConceptScore W2142629029C112705442 @default.
• W2142629029 hasConceptScore W2142629029C126322002 @default.
• W2142629029 hasConceptScore W2142629029C185592680 @default.
• W2142629029 hasConceptScore W2142629029C197934379 @default.
• W2142629029 hasConceptScore W2142629029C22979827 @default.
• W2142629029 hasConceptScore W2142629029C2776202225 @default.
• W2142629029 hasConceptScore W2142629029C2778305200 @default.
• W2142629029 hasConceptScore W2142629029C2778375690 @default.
• W2142629029 hasConceptScore W2142629029C2780580376 @default.
• W2142629029 hasConceptScore W2142629029C2780852908 @default.
• W2142629029 hasConceptScore W2142629029C29730261 @default.
• W2142629029 hasConceptScore W2142629029C55493867 @default.
• W2142629029 hasConceptScore W2142629029C64927066 @default.
• W2142629029 hasConceptScore W2142629029C71924100 @default.
• W2142629029 hasConceptScore W2142629029C90924648 @default.
• W2142629029 hasConceptScore W2142629029C98274493 @default.
• W2142629029 hasIssue "3" @default.
• W2142629029 hasLocation W21426290291 @default.
• W2142629029 hasLocation W21426290292 @default.
• W2142629029 hasOpenAccess W2142629029 @default.

• next